Neurotrophic factors in Alzheimer’s disease: role of axonal transport

Abstract

Neurotrophic factors (NTF) are small, versatile proteins that maintain survival and function to specific neuronal populations. In general, the axonal transport of NTF is important as not all of them are synthesized at the site of its action. Nerve growth factor (NGF), for instance, is produced in the neocortex and the hippocampus and then retrogradely transported to the cholinergic neurons of the basal forebrain. Neurodegenerative dementias like Alzheimer’s disease (AD) are linked to deficits in axonal transport. Furthermore, they are also associated with imbalanced distribution and dysregulation of NTF. In particular, brain‐derived neurotrophic factor (BDNF) plays a crucial role in cognition, learning and memory formation by modulating synaptic plasticity and is, therefore, a critical molecule in dementia and neurodegenerative diseases. Here, we review the changes of NTF expression and distribution (NGF, BDNF, neurotrophin‐3, neurotrophin‐4/5 and fibroblast growth factor‐2) and their receptors [tropomyosin‐related kinase (Trk)A, TrkB, TrkC and p75 NTR ] in AD and AD models. In addition, we focus on the interaction with neuropathological hallmarks Tau/neurofibrillary tangle and amyloid‐β (Abeta)/amyloid plaque pathology and their influence on axonal transport processes in order to unify AD‐specific cholinergic degeneration and Tau and Abeta misfolding through NTF pathophysiology.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 199

1. 1.

   Adalbert R, Gilley J, Coleman MP. Abeta, tau and ApoE4 in Alzheimer’s disease: the axonal connection. Trends Mol Med. 2007;13:135-142.

   Not in our library10.1016/j.molmed.2007.02.004

2. 2.

   Akatsu H, Yamagata HD, Kawamata J, Kamino K, Takeda M, Yamamoto T, Miki T, Tooyama I, Shimohama S, Kosaka K. Variations in the BDNF gene in autopsy-confirmed Alzheimer’s disease and dementia with Lewy bodies in Japan. Dement Geriatr Cogn Disord. 2006;22:216-222.

   Not in our library10.1159/000094933

3. 3.

   Allen SJ, Wilcock GK, Dawbarn D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer’s disease. Biochem Biophys Res Commun. 1999;264:648-651.

   Not in our library10.1006/bbrc.1999.1561

4. 4.

   Ambree O, Leimer U, Herring A, Gortz N, Sachser N, Heneka MT, Paulus W, Keyvani K. Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways. Am J Pathol. 2006;169:544-552.

   Not in our library10.2353/ajpath.2006.051107

5. 5.

   Araujo DM, Cotman CW. Basic FGF in astroglial, microglial, and neuronal cultures: characterization of binding sites and modulation of release by lymphokines and trophic factors. J Neurosci. 1992;12:1668-1678.

   Not in our library10.1523/jneurosci.12-05-01668.1992

6. 6.

   Arenas E, Persson H. Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature. 1994;367:368-371.

   Not in our library10.1038/367368a0

7. 7.

   Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease. Acta Neuropathol (Berl). 1983;61:101-108.

   Not in our library10.1007/bf00697388

8. 8.

   Babu JR, Geetha T, Wooten MW. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem. 2005;94:192-203.

   Not in our library10.1111/j.1471-4159.2005.03181.x

9. 9.

   Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H. Globular amyloid beta-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem. 2005;95:834-847.

   Not in our library10.1111/j.1471-4159.2005.03407.x

10. 10.

    Bauer M, Alda M, Priller J, Young LT. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry. 2003;36(Suppl. 3):S250-S254.

    Not in our library10.1055/s-2003-45138

11. 11.

    Bergeron C, Pollanen MS, Weyer L, Lang AE. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol. 1997;56:726-734.

    Not in our library

12. 12.

    Bian JT, Zhang JW, Zhang ZX, Zhao HL. Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer’s disease (AD) in mainland Chinese. Neurosci Lett. 2005;387:11-16.

    Not in our library10.1016/j.neulet.2005.07.009

13. 13.

    Boissiere F, Hunot S, Faucheux B, Hersh LB, Agid Y, Hirsch EC. Trk neurotrophin receptors in cholinergic neurons of patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 1997;8:1-8.

    Not in our library10.1159/000106594

14. 14.

    Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.

    Not in our library10.1007/bf00308809

15. 15.

    Brendza RP, Simmons K, Bales KR, Paul SM, Goldberg MP, Holtzman DM. Use of YFP to study amyloid-beta associated neurite alterations in live brain slices. Neurobiol Aging. 2003;24:1071-1077.

    Not in our library10.1016/j.neurobiolaging.2003.04.008

16. 16.

    Burack MA, Halpain S. Site-specific regulation of Alzheimer-like tau phosphorylation in living neurons. Neuroscience. 1996;72:167-184.

    Not in our library10.1016/0306-4522(95)00546-3

17. 17.

    Burbach GJ, Hellweg R, Haas CA, Del Turco D, Deicke U, Abramowski D, Jucker M, Staufenbiel M, Deller T. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci. 2004;24:2421-2430.

    Not in our library10.1523/jneurosci.5599-03.2004

18. 18.

    Busciglio J, Lorenzo A, Yeh J, Yankner BA. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995;14:879-888.

    Not in our library10.1016/0896-6273(95)90232-5

19. 19.

    Butt AM, Dinsdale J. Fibroblast growth factor 2 mediated disruption of myelin-forming oligodendrocytes in vivo is associated with increased tau immunoreactivity. Neurosci Lett. 2005;375:28-32.

    Not in our library10.1016/j.neulet.2004.10.060

20. 20.

    Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A. 2002;99:12432-12437.

    Not in our library10.1073/pnas.192442999

21. 21.

    Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, Eckman C, Meiners J, Nilsen SP, Younkin SG, Hsiao KK. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet. 1997;6:1951-1959.

    Not in our library10.1093/hmg/6.11.1951

22. 22.

    Chee FC, Mudher A, Cuttle MF, Newman TA, MacKay D, Lovestone S, Shepherd D. Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis. 2005;20:918-928.

    Not in our library10.1016/j.nbd.2005.05.029

23. 23.

    Chen MJ, Russo-Neustadt AA. Exercise activates the phosphatidylinositol 3-kinase pathway. Brain Res Mol Brain Res. 2005;135:181-193.

    Not in our library10.1016/j.molbrainres.2004.12.001

24. 24.

    Cheng B, Mattson MP. Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bFGF. Exp Neurol. 1992;117:114-123.

    Not in our library10.1016/0014-4886(92)90120-f

25. 25.

    Chu Y, Cochran EJ, Bennett DA, Mufson EJ, Kordower JH. Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer’s disease. J Comp Neurol. 2001;437:296-307.

    Not in our library10.1002/cne.1284

26. 26.

    Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol. 2004;16:83-90.

    Not in our library10.1615/critrevneurobiol.v16.i12.90

27. 27.

    Chuu JY, Taylor JL, Tinklenberg J, Noda A, Yesavage J, Murphy GM. The brain-derived neurotrophic factor Val66Met polymorphism and rate of decline in Alzheimer’s disease. J Alzheimers Dis. 2006;9:43-49.

    Not in our library10.3233/jad-2006-9104

28. 28.

    Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-b levels in vivo. Neuron. 2005;48:913-922.

    Not in our library10.1016/j.neuron.2005.10.028

29. 29.

    Combarros O, Infante J, Llorca J, Berciano J. Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004;18:55-58.

    Not in our library10.1159/000077736

30. 30.

    Connor B, Young D, Lawlor P, Gai W, Waldvogel H, Faull RL, Dragunow M. Trk receptor alterations in Alzheimer’s disease. Brain Res Mol Brain Res. 1996;42:1-17.

    Not in our library10.1016/s0169-328x(96)00040-x

31. 31.

    Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain Res. 1997;49:71-81.

    Not in our library10.1016/s0169-328x(97)00125-3

32. 32.

    Costantini C, Weindruch R, Della Valle G, Puglielli L. A TrkA-to-p75NTR molecular switch activates amyloid beta-peptide generation during aging. Biochem J. 2005;391:59-67.

    Not in our library10.1042/bj20050700

33. 33.

    Costantini C, Scrable H, Puglielli L. An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide generation. EMBO J. 2006;25:1997-2006.

    Not in our library10.1038/sj.emboj.7601062

34. 34.

    Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer’s disease. Ann Neurol. 2004;56:520-531.

    Not in our library10.1002/ana.20233

35. 35.

    Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer’s disease. J Neurosci. 1993;13:2540-2550.

    Not in our library10.1523/jneurosci.13-06-02540.1993

36. 36.

    Cummings BJ, Su JH, Cotman CW. Neuritic involvement within bFGF immunopositive plaques of Alzheimer’s disease. Exp Neurol. 1993;124:315-325.

    Not in our library10.1006/exnr.1993.1202

37. 37.

    da Penha Berzaghi M, Cooper J, Castrén E, Zafra F, Sofroniew M, Thoenen H, Lindholm D. Cholinergic regulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) but not neurotrophin-3 (NT-3) mRNA levels in the developing rat hippocampus. J Neurosci. 1993;13:3813-3826.

    Not in our library10.1523/jneurosci.13-09-03818.1993

38. 38.

    Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease. Neurology. 2002;59:398-407.

    Not in our library10.1212/wnl.59.3.398

39. 39.

    De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, Cattaneo A. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A. 2005;102:3811-3816.

    Not in our library10.1073/pnas.0500195102

40. 40.

    Desai P, Nebes R, DeKosky ST, Kamboh MI. Investigation of the effect of brain-derived neurotrophic factor (BDNF) polymorphisms on the risk of late-onset Alzheimer’s disease (AD) and quantitative measures of AD progression. Neurosci Lett. 2005;379:229-234.

    Not in our library10.1016/j.neulet.2005.01.008

Cited by papers we hold 9

• Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer’s Disease Progression · 2023
  No notice
• Combination Drug Therapy for the Management of Alzheimer’s Disease · 2020
  No notice
• Neural stem cell-derived small extracellular vesicles attenuate apoptosis and neuroinflammation after traumatic spinal cord injury by activating autophagy · 2019
  No notice
• Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid β · 2018
  Not checked
• Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches · 2018
  No notice
• Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease · 2015
  Not checked
• Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction · 2014
  No notice
• A Large, Cross-Sectional Observational Study of Serum BDNF, Cognitive Function, and Mild Cognitive Impairment in the Elderly · 2014
  No notice
• TrkB Receptor Signalling: Implications in Neurodegenerative, Psychiatric and Proliferative Disorders · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.